There has been an increased demand for products that fight against harmful UVB and UVA radiation in recent years. However, innovation and technology have proven the non-existence of limitations to have such products on board. Kannalife, Inc. (OTCQB: KLFE) has identified Atopidine, an Atopidine, which has demonstrated protective and anti-inflammatory properties. The novel molecule outdid cannabidiol (CBD) in inhibiting inflammatory responses pertinent to UVB-radiation through pre-clinical testing and scientific comparisons.
The new unfolding has resulted in issuing a Notice of Allowance to the biopharmaceutical medchem company from the USUnited States Patent and Trademark Office (USPTO) for trademark application of Atopidine. It will represent Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine (“LEA”). And while there have been rising concerns regarding skin problems, Atopidine can decrease inflammatory cytokine levels at concentrations 50 times less than toxic levels. As a result, Kannalife, Inc. expects to have the finished product of Atopidine™ hit the marker soon for commercial use to address the global market size for skincare products estimated to reach $183.03 billion by 2025.
Kannalife is Exclusively Positioned in the Development of Potent Novel Monotherapeutics
Chemotherapy-induced peripheral neuropathy (CIPN) and hepatic encephalopathy (HE) are common Neurodegenerative disorders today. However, Kannalife, Inc. is putting a lot of focus on developing monotherapeutic products to meet the unmet medical needs of such disorders. KLS-13019 is one such potential treatment awaiting the US Food and Drug Administration’s (FDA) approval.
Meanwhile, to offer added support to its operations, Kannalife has picked on Dr. Tage Honoré to Chair the Company’s Board of Advisors. The world-renowned pharma and biotechnology executive is a pioneer with expert knowledge in several fields, including Alzheimer’s diseases, earning disorders, cancer immunotherapy, and female hormone replacement therapy (HRT).
He has developed organizational models for several companies, published more than 100 scientific papers, championed 40 drugs to progress from idea to clinical development, and is also the inventor on 23 patents.
“…His clinical drug development experience and knowledge in the CNS and PNS space is invaluable and timely to our current efforts to head towards the clinic with KLS-13019,” Dean Petkanas, CEO of Kannalife, commented.
The Green Organic Dutchman Holdings (OTC: TGODF) Releases an Update on its Canadian Securities Exchange Listing
Post Views: 4 The Green Organic Dutchman Holdings (OTC: TGODF) is a top producer of organically-grown, premium certified marijuana, and it...
Next Green Wave Holdings Inc (OTCMKTS: NXGWF) Announces the Resignation of One of Its Directors
Post Views: 55 Next Green Wave Holdings Inc (OTCMKTS: NXGWF) recently announced that a Director had resigned from this position. The...
AFC Gamma Inc (NASDAQ: AFCG) Increases Quarterly Dividend by 13.2% per Share, and the Group Expands its Senior Secured Credit Facility with Devi Holdings, Inc. by $30 Million
Post Views: 26 AFC Gamma Inc (NASDAQ: AFCG) recently announced a dividend for the quarter ending September 30, 2021. The...
TerrAscend Corp (OTCMKTS: TRSSF) Acquisition of Gage Cannabis Receives Pre-Qualification Approval
Post Views: 53 TerrAscend Corp (OTCMKTS: TRSSF) is a leading cannabis operator based in North America that recently announced it had...
Jushi Holdings Inc (OTCMKTS: JUSHF) Opens 15th Store in Pennsylvania, Acquires Nature’s Remedy, and Announced Launch of Flower Brands
Post Views: 2 Jushi Holdings Inc (OTCMKTS: JUSHF), through its subsidiary, Franklin Bioscience – SE LLC. BEYOND / HELLO™ Colwyn...
FinCanna Capital Corp (OTCMKTS: FNNZF) Set to launch its “Big Fish” Cannabis-Based Edibles Brand
Post Views: 3 FinCanna Capital Corp (OTCMKTS: FNNZF) is an investment corporation for the United States licensed cannabis market that recently...